Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia

Imatinib mesylate (IM), a targeted competitive inhibitor of the BCR-ABL tyrosine kinase, has revolutionized the clinical treatment of chronic myeloid leukemia (CML). However, resistance and intolerance are still a challenge in the treatment of CML. Autophagy has been proposed to play a role in IM re...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Shan, Li, Su, Qin, Youwen, Wang, Xiaorui, Yang, Yining, Bai, Haitao, Zhou, Lili, Zhao, Chuxian, Wang, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904104/
https://www.ncbi.nlm.nih.gov/pubmed/24585095
http://dx.doi.org/10.3892/ijo.2014.2313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904104/
https://www.ncbi.nlm.nih.gov/pubmed/24585095
http://dx.doi.org/10.3892/ijo.2014.2313

Ejemplares similares